Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony Mok, Nelly Cherciu, Kaoru Kubota et al.|The Lancet|2019Cited by 3.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyNicole M. Kuderer, Kerry L. Reynolds, Toni K. Choueiri et al.|The Lancet|2020Cited by 1.8k
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort StudyDonna R. Rivera, Jeremy L. Warner, Solange Peters et al.|Cancer Discovery|2020Cited by 138
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With<i>EGFR</i>-Mutated Advanced Non–Small Cell Lung CancerPedro Nazareth Aguiar, Gilberto Lopes|JAMA Oncology|2018Cited by 121
Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) RegistryAng Li, Rachel Rosovsky, Nicole M. Kuderer et al.|Blood|2020Cited by 8